Ferrer da un paso más en su estrategia y desinvierte en HealthTech BioActives . Vie, 13/12/2019 - 11:34
Ferrer takes a big step forward with its business strategy and divests in HealthTech BioActives . Vie, 13/12/2019 - 11:34
Luqa Pharmaceuticals and Ferrer Internacional S.A. announce that they have entered into an exclusive agreement to develop and commercialize OZENOXACIN for the treatment of impetigo in China . Mar, 09/04/2019 - 11:30
Three Spanish public hospitals study the safety and efficacy of the first cell therapy to treat acute traumatic spinal cord injury . Mar, 22/05/2018 - 11:32